Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Hims & Hers (HIMS ... some compounded versions of weight-loss drugs. The company's fourth quarter results came in better than expected. But investors were spooked over the potential loss in revenue ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading. Revenue increased 95% from a year earlier to $481 million ...

I expect price sensitive consumers to flood the market for compounded GLP-1 drugs before the 60-day FDA grace period for semaglutide compounders. HIMS projects $725M in GLP-1 weight loss revenue ...

GLP-1 drugs, also known as incretin treatments ... developing next-generation treatments with stronger weight-loss effects. Others, like Hims & Hers (HIMS), betted on more affordable off-brand ...

Hims & Hers (HIMS) stock plunged 27% on Tuesday after the telehealth highflier indicated it may soon stop offering some compounded versions of weight-loss drugs. The company's fourth quarter ...